VolitionRx Limited (VNRX)
| Market Cap | 2.68M -94.6% |
| Revenue (ttm) | 2.46M +86.3% |
| Net Income | -26.10M |
| EPS | -3.80 |
| Shares Out | 14.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,431,854 |
| Open | 0.1800 |
| Previous Close | 0.1790 |
| Day's Range | 0.1800 - 0.1938 |
| 52-Week Range | 0.1748 - 10.3140 |
| Beta | 1.17 |
| Analysts | Buy |
| Price Target | 13.62 (+7,125.46%) |
| Est. Earnings | Nov 12, 2026 |
About VNRX
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s c... [Read more]
Financial Performance
In 2025, VolitionRx's revenue was $1.73 million, an increase of 40.04% compared to the previous year's $1.23 million. Losses were -$23.36 million, -13.39% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for VNRX stock is "Buy." The 12-month stock price target is $13.62, which is an increase of 7,125.46% from the latest price.
News
VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
HENDERSON, Nev., Sept. 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ( XASE: VNRX) (together with affiliates "Volition"), a multi-national epigenetics company, as part of the Gov...
VolitionRx Participates in Launch of DETECSEPS Program in France
French Government-Funded €6.3 million (~$7.3 million) Consortium Selects Volition's Nu.Q® NETs Assay as Sole Biomarker for France's Real World Evaluation of Early Detection of Sepsis HENDERSON, Nev.,...
VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027
Reduces Equity Overhang HENDERSON, Nev., Sept. 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-paymen...
VolitionRx presents early stage I solid cancer detection at ESMO MAP Conference
VolitionRx (VNRX) announced the presentation of an abstract at the European Society of Medical Oncology Molecular Analysis for Precision Oncology Conference – ESMO MAP – in London this week. The…
Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
Targets $36 Billion TAM in Early Cancer Detection and MRD. HENDERSON, Nev.
VolitionRx Slides: Corporate presentation
VolitionRx has posted slides in relation to its latest quarterly earnings report, which was published on September 10, 2026.
VolitionRx Registration statement: Registration filing
VolitionRx filed a registration statement on September 9, 2026, providing details about a securities offering with the SEC.
VolitionRx Registration statement: Registration filing
VolitionRx filed a registration statement on September 8, 2026, providing details about a securities offering with the SEC.
VolitionRx files to sell 10.01M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 10.01M shares of common stock. The company is not selling any…
VolitionRx Registration statement: Registration filing
VolitionRx filed a registration statement on August 28, 2026, providing details about a securities offering with the SEC.
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
112% H1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders HENDERSON, Nev.,...
VolitionRx announces publication on Nu.Q NETs H3.1 biomarker
VolitionRx (VNRX) announced the publication of a peer-reviewed paper and independent Editorial which reported that its Nu.Q NETs H3.1 biomarker is an independent predictor of 28-day mortality and need...
Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis
Published in Critical Care Medicine , findings confirm high-predictive accuracy for severe sepsis outcomes, driving commercial momentum across Volition's $2.8 billion addressable market. HENDERSON, Ne...
VolitionRx reports results from lateral flow finger prick sample test for sepsis
VolitionRx (VNRX) announces that results utilizing its lateral flow prototype are highly correlated with results utilizing Volition’s established automated Nu.Q NETs test in critically ill sepsis pati...
VolitionRx reports Q2 revenue $400K, consensus $474.34K
CEO Cameron Reynolds said, “We have made strong progress across all of our product pillars throughout 2026 to date. We are currently in discussions, including undertaking technology evaluations, with ...
VolitionRx Earnings Call Transcript: Q2 2026
Strong clinical and commercial progress was made across all product lines, with major advances in sepsis, cancer, and veterinary diagnostics. Revenue was flat in Q2 but up 112% for the first half, while operating expenses fell 32% year-over-year. Multiple licensing and reimbursement milestones are anticipated.
VolitionRx Earnings release: Q2 2026
VolitionRx released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
VolitionRx Quarterly report: Q2 2026
VolitionRx has published its Q2 2026 quarterly earnings report on August 14, 2026.
VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Friday, August 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
VolitionRx Slides: Corporate presentation
VolitionRx has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
Removes Centralized Lab Dependency for $3.8 Billion Global Addressable Market for NETosis Testing HENDERSON, Nev., Aug. 12, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), ...
VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update
Conference call to take place on Friday, August 14 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization.
VolitionRx Slides: Corporate presentation
VolitionRx has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Volition Advances Nu.Q® NETs Platform Towards Commercialization
Consistent international data positions Nu.Q® H3.1 as a potential "game changer" in sepsis management within a $3.8 billion addressable market HENDERSON, Nev., July 30, 2026 /PRNewswire/ -- VolitionRx...